Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Deferred Taxes (2021 - 2025)

Barinthus Biotherapeutics' Deferred Taxes history spans 5 years, with the latest figure at -$57000.0 for Q4 2025.

  • For Q4 2025, Deferred Taxes fell 2000.0% year-over-year to -$57000.0; the TTM value through Dec 2025 reached -$175000.0, down 297.73%, while the annual FY2025 figure was -$175000.0, 297.73% down from the prior year.
  • Deferred Taxes reached -$57000.0 in Q4 2025 per BRNS's latest filing, up from -$71000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $3000.0 in Q4 2024 to a low of -$1.9 million in Q4 2022.
  • Average Deferred Taxes over 5 years is -$387500.0, with a median of -$57000.0 recorded in 2021.
  • Peak YoY movement for Deferred Taxes: crashed 12971.43% in 2022, then surged 100.37% in 2024.
  • A 5-year view of Deferred Taxes shows it stood at -$57000.0 in 2021, then tumbled by 3292.98% to -$1.9 million in 2022, then surged by 57.55% to -$821000.0 in 2023, then soared by 100.37% to $3000.0 in 2024, then tumbled by 2000.0% to -$57000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Deferred Taxes are -$57000.0 (Q4 2025), -$71000.0 (Q3 2025), and -$25000.0 (Q2 2025).